Shield Therapeutics PLC 2019 Annual Report and 2020 AGM Notice (8031N)
May 22 2020 - 10:15AM
UK Regulatory
TIDMSTX
RNS Number : 8031N
Shield Therapeutics PLC
22 May 2020
Shield Therapeutics plc
("Shield" or the "Group" or the "Company")
2019 Annual Report and 2020 AGM Notice
London, UK, 22 May 2020: Shield Therapeutics plc (LSE: STX), a
commercial stage, pharmaceutical company with a focus on addressing
iron deficiency with its lead product Feraccru (R)/Accrufer(R)
(ferric maltol), a novel oral iron treatment, announces that the
following documents have now been sent to shareholders:
-- Annual Report and Accounts for the year ended 31 December 2019
-- Notice of Annual General Meeting ("AGM") 2020
In accordance with AIM Rule 26, these documents are also
available to view on the Company's website
www.shieldtherapeutics.com/investors/corporate-documents/ .
The AGM is scheduled to be held at 1.00pm BST on Thursday 18
June 2020. Due to COVID-19 and the latest "stay at home"
restrictions, this meeting will be held virtually, and attendance
will be available online and telephonically.
The Company will provide a facility for shareholders to join the
AGM online and telephonically and there will be an opportunity for
shareholders to ask questions. In order to facilitate the process,
the Board would request that shareholders register for the meeting
and submit questions in advance, before 5.00pm (BST) on 16 June
2020.
To register for dial-in details and to submit any questions
please contact Walbrook PR via email at shield@walbrookpr.com or
call +44 (0)20 7933 8787.
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Tim Watts, CEO +44 (0)20 7186 8500
Karen Chandler Smith, Investor
Relations
Nominated Adviser and Joint
Broker
Peel Hunt LLP
James Steel/Dr Christopher
Golden +44 (0)20 7418 8900
Joint Broker
finnCap Ltd
Geoff Nash/Matt Radley/Alice
Lane +44 (0)20 7220 0500
Financial PR & IR Advisor
Walbrook PR +44 (0)20 7933 8780 or shield@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7584 391
Paul McManus/Lianne Cawthorne 303
About Shield Therapeutics plc
Shield is a de-risked, commercial stage, specialty
pharmaceutical company delivering innovative pharmaceuticals to
address patients' unmet medical needs. The Company's clear purpose
is to develop products that help patients become people again,
enabling them to enjoy the things that make a difference in their
everyday lives . The Group's lead product, Feraccru (R) / Accrufer
(R) has exclusive IP rights until the mid-2030s and is approved for
the treatment of iron deficiency with or without anaemia in adults
in the European Union, the United States and Switzerland. In Europe
it is marketed as Feraccru (R) with commercialisation led by
Norgine BV and in the USA the product will be marketed as Accrufer
(R) with Shield currently in the process of selecting a
commercialisation partner. Shield also has an exclusive licence
agreement with Beijing Aosaikang Pharmaceutical Co. Ltd for the
development and commercialisation of Feraccru(R)/Accrufer(R) in
China, Hong Kong, Macau and Taiwan. For more information please
visit www.shieldtherapeutics.com
About Feraccru(R)/Accrufer(R)
Feraccru (R) /Accrufer(R) is a novel, stable, non-salt based
oral therapy for adults with iron deficiency with or without
anaemia that has been shown to be an efficacious and well-tolerated
therapy in a range of controlled phase 3 trials, and offers a
compelling alternative to IV iron for those patients unable to
tolerate salt-based oral iron therapies and wish to avoid the
complexities of infusion-based iron therapies.
When salt-based oral iron therapies are ingested they can cause
a range of mild-to-severe gastrointestinal tract (GI) adverse
events, including nausea, bloating and constipation through the
release and subsequent reactivity of free iron in the GI tract,
leading to poor tolerability, reduced patient compliance and
ultimately treatment failure. Feraccru (R) /Accrufer(R) is not an
iron salt and, as a result, it does not routinely cause the same
treatment-limiting intolerance issues of salt-based iron therapies,
whilst the iron from the ferric maltol molecule can be readily
absorbed.
Prior to Feraccru (R) /Accrufer(R) , IV iron therapies were the
only realistic alternative treatment option for iron deficient
patients with or without anaemia intolerant of or unwilling to be
treated salt-based oral iron therapies. However, use of such an
invasive, costly, inconvenient and complex to administer treatment
option, which is associated with potentially life-threatening and
spontaneous hypersensitivity reactions, means there remains a clear
unmet medical need for these patients to have access to an
effective therapy that is well tolerated, convenient and does not
require hospital-based administration. Feraccru (R) /Accrufer(R)
meets those requirements.
About Iron Deficiency
The WHO states that iron deficiency is the most common and
widespread nutritional disorder in the world. As well as affecting
a large number of women and children in non-industrialized
countries, it is the only nutrient deficiency which is also
significantly prevalent in virtually all industrialised nations.
There are no current global figures for iron deficiency but, using
anaemia as an indirect indicator, it can be estimated that most
preschool children and pregnant women in non-industrialised
countries, together with at least 30-40% in industrialized
countries, are iron deficient.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ACSMZGZKKZZGGZM
(END) Dow Jones Newswires
May 22, 2020 11:15 ET (15:15 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2023 to Apr 2024
